Caicun Zhou

机构：Tongji University, First Affiliated Hospital of Guangzhou Medical University, Shanghai Pulmonary Hospital, Shanghai East Hospital, Guangzhou Medical University · ORCID：0000-0002-2246-5541

发表论文 242 篇 · 总被引 35796 次 · h-index 57

代表论文

• First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC (2023 · New England Journal of Medicine · 被引 227)
• Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer (2024 · JAMA Oncology · 被引 63)
• Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations (2024 · European Journal of Cancer · 被引 29)
• Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 17)
• First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC). (2025 · Journal of Clinical Oncology · 被引 14)
• Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study (2024 · Journal of Hematology & Oncology · 被引 14)